Palbociclib
Showing 1 - 25 of 348
Breast Cancer Trial in Orange City (ARV-471 (PF-07850327), Palbociclib, Letrozole)
Recruiting
- Breast Cancer
- ARV-471 (PF-07850327)
- +2 more
-
Orange City, FloridaMid Florida Hematology and Oncology Center
Jun 8, 2023
Metastatic Breast Cancer Trial in Al Madinah (Palbociclib)
Not yet recruiting
- Metastatic Breast Cancer
- Palbociclib
-
Al Madīnah, AL, Saudi ArabiaAsmaa Imam Ahmed
Oct 8, 2023
Palbociclib in Canadian Breast Cancer That Has Spread to Other
Not yet recruiting
- Breast Cancer
- Palbociclib
- (no location specified)
Aug 18, 2023
Undifferentiated Pleomorphic Sarcoma Trial in Iowa City (Palbociclib, Pembrolizumab)
Not yet recruiting
- Undifferentiated Pleomorphic Sarcoma
- Palbociclib
- Pembrolizumab
-
Iowa City, IowaUniversity of Iowa Hospitals & Clinics
Nov 1, 2023
Compare Overall Survival in Medicare Metastatic Breast Cancer
Active, not recruiting
- Breast Cancer
- Palbociclib
- Aromatase Inhibitor
-
New York, New YorkPfizer New York
Oct 11, 2023
Advanced Breast Cancer, Treatment-Refractory Solid Tumors, Retinoblastoma Deficiency Trial in Providence (Palbociclib Oral
Not yet recruiting
- Advanced Breast Cancer
- +6 more
- Palbociclib Oral Product
- TAS-116
-
Providence, Rhode IslandLifespan Cancer Institute
Feb 1, 2023
DCIS Trial in Washington (Palbociclib)
Recruiting
- DCIS
- Palbociclib
-
Washington, District of Columbia
- +1 more
Jan 23, 2023
Breast Tumor Female Trial in Beijing (CDK4/6 inhibitor (Qilu),Trastuzumab (Hanquyou))
Recruiting
- Breast Neoplasm Female
- CDK4/6 inhibitor (Qilu),Trastuzumab (Hanquyou)
-
Beijing, Beijing, China
- +1 more
Jul 31, 2023
Esophagus Squamous Cell Carcinoma Trial in Beijing (Palbociclib, Afatinib)
Recruiting
- Esophagus Squamous Cell Carcinoma
- Palbociclib
- Afatinib
-
Beijing, Beijing, ChinaNational Cancer Center/Cancer Hospital, Chinese Academy of Medic
May 17, 2023
Breast Cancer Trial in Groningen (Palbociclib, FES PET, Letrozole)
Completed
- Breast Cancer
- Palbociclib
- +2 more
-
Groningen, NetherlandsUniversity Medical Center Groningen
Oct 11, 2022
Advanced Dedifferentiated Liposarcoma, Locally Advanced Dedifferentiated Liposarcoma, Metastatic Dedifferentiated Liposarcoma
Not yet recruiting
- Advanced Dedifferentiated Liposarcoma
- +5 more
- Palbociclib
- +5 more
- (no location specified)
Jan 11, 2023
Head Neck Cancer, Locally Advanced Trial in Bangkok (Palbociclib, Cetuximab, Intensity Modulated Radiation Therapy)
Active, not recruiting
- Head and Neck Cancer
- Locally Advanced
- Palbociclib
- +2 more
-
Bangkok, ThailandFaculty of Medicine, Ramathibodi Hospital
Sep 19, 2022
Breast Cancer, Hormone Receptor-positive Breast Cancer, Hormone Therapy Trial in Taipei City, Taipei (Palbociclib, Ribociclib,
Recruiting
- Breast Cancer
- +2 more
- Palbociclib
- +3 more
-
Taipei City, Taiwan
- +1 more
Mar 15, 2023
Hepatic Impairment and Myelosuppression in Breast Cancer
Not yet recruiting
- Breast Cancer
- (no location specified)
Jun 11, 2023
COVID-19 Trial in Brandenburg an der Havel (Palbociclib)
Withdrawn
- COVID-19
- Palbociclib
-
Brandenburg an der Havel, GermanyUniversitätsklinikum Brandenburg an der Havel
Nov 3, 2022
Learn About Dangers Linked to Myelosuppression in Breast Cancer
Not yet recruiting
- Breast Cancer
- (no location specified)
Jan 24, 2023
Tumor, Solid, Pancreatic Cancer Trial in Chapel Hill (Ulixertinib, Palbociclib)
Recruiting
- Tumor, Solid
- +2 more
- Ulixertinib
- Palbociclib
-
Chapel Hill, North CarolinaLineberger Comprehensive Cancer Center
Nov 30, 2022
Renal Cell Carcinoma, Ovarian Carcinoma, Thyroid Carcinoma Trial in Groningen (Olaparib, Lenvatinib, Sunitinib)
Not yet recruiting
- Renal Cell Carcinoma
- +4 more
- Olaparib
- +4 more
-
Groningen, NetherlandsUniversity Medical Center Groningen
Jul 13, 2023
Breast Cancer Stage IV, Unresectable Locally Advanced Invasive Breast Cancer, Metastatic Invasive Breast Cancer Trial in Boston
Completed
- Breast Cancer Stage IV
- +2 more
- Palbociclib
- Bazedoxifene
-
Boston, Massachusetts
- +1 more
Oct 21, 2022
Inhibition of Autophagy Synergizes Anti-tumor Effect Trial in Guangzhou (100mg bid dose of hydroxychloroquine combined with
Recruiting
- Inhibition of Autophagy Synergizes Anti-tumor Effect
- 100mg bid dose of hydroxychloroquine combined with three predefined dose groups of palbociclib
- RP2D dose of 100mg bid of hydroxychloroquine combined with palbociclib was selected for phase II clinical trial.
-
Guangzhou, Guangdong, ChinaSun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Jul 19, 2023
Real-World Evidence In Patients Treated With Palbociclib
Recruiting
- Metastatic Breast Cancer
- Palbociclib
-
Timisoara, Timiș, Romania
- +5 more
Dec 7, 2022
Breast Cancer, Head Neck Cancer Trial in Seoul (Palbociclib, Cetuximab, Fulvestrant)
Recruiting
- Breast Cancer
- Head and Neck Cancer
- Palbociclib
- +3 more
-
Seoul, Seoul-teukbyeolsi [seoul], Korea, Republic of
- +3 more
Dec 14, 2022
Metastatic Breast Cancer (MBC) Trial in United States (Palbociclib, Bicalutamide)
Active, not recruiting
- Metastatic Breast Cancer (MBC)
- Palbociclib
- Bicalutamide
-
Basking Ridge, New Jersey
- +4 more
Oct 31, 2022
Describe Breast Cancer Patient Population, Treatment, and
Completed
- Breast Cancer
- +4 more
- Palbociclib plus hormonal treatment - first line treatment
- Palbociclib plus hormonal treatment - second line treatment
-
Rajpath Club Lane ,Gujarat, India, Ahmedabad, India
- +5 more
Oct 13, 2022